Bertolt Kreft

Bertolt Kreft has served as Chief Scientific Officer since February 2020. Bertolt is an expert in cancer drug discovery with 20 years of pharmaceutical industry experience and a broad background in oncology research covering target validation, biologics and small molecule lead discovery, as well as research supporting pre-IND, early and late-stage clinical development programs. Prior to joining Bright Peak, Bertolt served as VP Immuno-Oncology at Bayer AG. From 2009 to 2020, he was responsible for cancer drug discovery efforts at Bayer focused on Immuno-Oncology, antibody-drug conjugates (ADC), and biologics. Bertolt entered pharmaceutical industry with Schering AG in 1999 where he held positions of increasing responsibility including group leader in target identification & validation. Bertolt received a PhD in biochemistry from the Free University Berlin/Charité (Germany), followed by a postdoctoral fellowship at University of North Carolina, Chapel Hill. He holds a diploma in biochemistry from the Free University Berlin.